NCT05583617 2026-03-06
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
Clinical Trials
36 trialsNCT04623541 2026-03-04
EPCORE™ CLL-1
Genmab
Phase 1/2 Active not recruiting
NCT04542824 2026-03-03
EPCORE™ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-03-03
EPCORE™ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT05950165 2026-03-03
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Cho Pharma Inc.
Phase 1/2 Recruiting
NCT04246086 2026-02-20
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06892522 2026-02-17
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
AbbVie
Phase 1/2 Recruiting
NCT04669171 2026-01-30
SIDNEY
Enterome
Phase 1/2 Recruiting
NCT05222555 2026-01-16
MINDway
Incyte Corporation
Phase 1/2 Active not recruiting
NCT02343042 2025-12-22
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Recruiting
NCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT04661007 2025-12-18
J-MIND
Incyte Corporation
Phase 1/2 Active not recruiting
NCT02180711 2025-10-15
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Acerta Pharma BV
Phase 1/2 Active not recruiting
NCT07210047 2025-10-07
Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients
HuniLife Biotechnology, Inc.
Phase 1/2 Enrolling by invitation
NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT06087653 2025-06-19
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Starton Therapeutics, Inc
Phase 1/2 Recruiting
NCT03544281 2025-03-18
DREAMM 6
GlaxoSmithKline
Phase 1/2 Completed
NCT05201248 2025-01-07
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
Genmab
Phase 1/2 Active not recruiting
NCT04110301 2024-11-20
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Beijing Mabworks Biotech Co., Ltd.
Phase 1/2 Recruiting
NCT01827137 2024-09-19
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Sellas Life Sciences Group
Phase 1/2 Completed
NCT02206425 2023-10-31
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Oncotherapeutics
Phase 1/2 Completed
NCT02685826 2023-10-06
A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma
Celgene
Phase 1/2 Completed
NCT05205252 2023-08-15
ARIA
Ipsen
Phase 1/2 Withdrawn
NCT01348919 2023-06-28
Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT02389543 2023-01-26
SLAM
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT03379051 2022-08-22
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
TG Therapeutics, Inc.
Phase 1/2 Terminated
NCT02631577 2022-04-13
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Hoffmann-La Roche
Phase 1/2 Completed
NCT02077166 2022-02-04
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Pharmacyclics LLC.
Phase 1/2 Completed
NCT01421186 2021-11-16
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
MorphoSys AG
Phase 1/2 Completed
NCT04882163 2021-10-05
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Phase 1/2 Withdrawn
NCT02265510 2020-04-17
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT02142049 2019-02-05
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Pharmacyclics LLC.
Phase 1/2 Completed
NCT01217957 2018-03-14
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Takeda
Phase 1/2 Completed
NCT00179712 2016-12-01
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Celgene Corporation
Phase 1/2 Completed
NCT00507442 2013-07-26
EVOLUTION
Millennium Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00179725 2006-04-12
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Celgene
Phase 1/2 Terminated